Sera Prognostics is trying to turn a validated preterm-birth blood test into a reimbursed franchise, and the second quarter shows how far that conversion still has to travel. Illinois enacted a Medicaid coverage mandate for proteomic preterm-risk testing, and a fourth partnership with a national payer launched after quarter-end. Peer-reviewed PRIME data now gives payers a randomized evidence package that earlier observational work never quite delivered. None of that has shown up as material recognized sales. The investment debate is whether access and evidence convert into paid tests before commercial spend consumes the cash cushion.
The tension sits on the balance sheet more than on the income statement. Cash and marketable securities totaled about $80 million at mid-year, enough in management's telling to fund operations through late decade. Against that pile sits a deferred-revenue liability of about $20 million that barely moved from year-end, the leftover of a large payer contract that has not been earned. Quarterly operating expenses ran about $10 million on recognized revenue of only $30 thousand. A reader who subtracts the deferred claim from cash is looking at an equity priced as a thin option on reimbursement, not as a going diagnostics business.
The print itself is almost beside the point except as a conversion scoreboard. Recognized sales of $30 thousand still covered none of the laboratory cost, let alone the commercial build. Selling and marketing stepped up while research spending included restructuring charges from a May staff cut. The questions that resolve the case over the next several quarters are specific. Illinois has to produce reimbursed volume. The dormant deferred-revenue contract has to start reversing into recognized sales. More than twenty payer discussions have to become signed coverage rather than another year of pipeline talk.